Lukas Linnig

Akribion Therapeutics is an early stage Biotech company developing precision oncology treatments. Using a groundbreaking new class of guided cytotoxic nucleases, Akribion aims to broaden the treatment landscape in critical therapeutic areas, with an initial focus in oncology through the use of highly selective cell depletion technology, enabled by specific targeting of RNA biomarkers. This unique technology platform is based on a proprietary family of nucleases termed G-dase® E. Akribion is committed to using its technology to improve patient treatment in compliance with high ethical standards. Akribion Therapeutics has been founded in 2024 by an expert team of scientists and Biotech executives, and is headquartered in Zwingenberg, Germany.